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Abstract
Background: Familial adenomatous polyposis (FAP) is a hereditary disorder characterized by polyposis along the
gastrointestinal tract. Information on adenoma status below the duodenum has previously been restricted due to
its inaccessibility in vivo. Capsule Endoscopy (CE) may provide a useful adjunct in screening for polyposis in the
small bowel in FAP patients. This study aims to evaluate the effectiveness of CE in the assessment of patients with
FAP, compared to other imaging modalities for the detection of small bowel polyps.
Method: 20 consecutive patients with previously diagnosed FAP and duodenal polyps, presenting for routine
surveillance of polyps at The Royal Melbourne Hospital were recruited. Each fasted patient initially underwent a
magnetic resonance image (MRI) of the abdomen, and a barium small bowel follow-through study. Capsule
Endoscopy was performed four weeks later on the fasted patient. An upper gastrointestinal side-viewing
endoscopy was done one (1) to two (2) weeks after this. Endoscopists and investigators were blinded to results of
other investigations and patient history.
Results: Within the stomach, upper gastrointestinal endoscopy found more polyps than other forms of imaging.
SBFT and MRI generally performed poorly, identifying fewer polyps than both upper gastrointestinal and capsule
endoscopy. CE was the only form of imaging that identified polyps in all segments of the small bowel as well as
the only form of imaging able to provide multiple findings outside the stomach/duodenum.
Conclusion: CE provides important information on possible polyp development distal to the duodenum, which
may lead to surgical intervention. The place of CE as an adjunct in surveillance of FAP for a specific subset needs
consideration and confirmation in replication studies.
Trial Registration: Australian New Zealand Clinical Trials Registry ACTRN12608000616370
Background
Polyps occur in the upper gastrointestinal tract in 30-
100% of patients with Familial Adenomatous Polyposis
[1,2]. Duodenal polyps (present in 45-90% of patients)
are usually adenomatous and have a 4-12% cancer risk.
Adenomas in the distal small bowel and in the stomach
have a lower cancer risk than duodenal adenomas,
although cancer in an ileostomy following colectomy
can occur [3-5]. The number of patients dying with ade-
nocarcinoma of unknown primary is not well
documented in the literature and could include patients
developing small-bowel cancer through an adenoma-
cancer pathway [6].
Screening of the upper gastrointestinal (GI) tract with
side-viewing (SV) endoscopy for gastric and duodenal
polyps has been recommended [7,8]. Other current techni-
ques, including small-bowel follow through (SBFT) and
MRI have had limited evaluation in the setting of FAP.
Since its advent in 2000 [9], capsule endoscopy (CE)
has proved useful for the investigation of the small
bowel [10,11]. CE offers potential advantages over other
forms of imaging, in terms of diagnostic sensitivity and
specificity, safety and tolerability [12,13]. Unlike most
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the entire small bowel, including jejunum and ileum.
Further exploration of the utility of CE may help to
identify if it is a useful adjunct to standard endoscopy as
a screening protocol in FAP. This could lead to more
accurate and earlier diagnosis of possible adenomatous
polyps, particularly if located in the jejunum and ileum,
potentially resulting in decreased morbidity and mortal-
ity rates for FAP patients.
The aim of this prospective blinded study was to
establish CE’s sensitivity and specificity for detection of
polyps in each part of the small bowel, compared with
other imaging modalities, in patients with FAP.
Methods
Twenty consecutive patients with previously diagnosed
FAP and duodenal polyps, presenting for routine duode-
nal surveillance at The Royal Melbourne Hospital were
recruited. Patients were considered eligible if they had
previously diagnosed FAP with duodenal polyps and
were over the age of 18 years old. Patients also must
have had clinical or X-ray assessments to assess poten-
tial obstruction of the small bowel before being consid-
ered for this study.
Exclusion criteria were suspected stenosis or obstruc-
tion of the small bowel, pregnancy, a swallowing disorder
that would preclude the safe ingestion of the capsule, car-
diac pacemaker or other implanted electromedical
devices. If a patient was expected to undergo MRI exami-
nation before the elimination of the capsule, they were
excluded as MRI scanning can potentially interfere with
transmission signals and may disrupt the integrity of the
capsule. The study protocol was approved by the
Melbourne Health Human Research Ethics Committee
and informed consent was obtained from each patient.
Each patient underwent four investigations to image
the bowel within a six week timeframe. Initially the
patient underwent a MRI of the abdomen. The MRI was
performed on the fasted patient and scanned using 1 litre
of dilute barium as intra luminal contrast. Scanning was
performed with 5/1 mm thick T2SSFSE and pre/post T1
fat-saturated GRE breath-hold sequences in the axial and
coronal planes. One week later, a barium SBFT study was
performed to exclude small bowel obstruction and as an
assessment of small bowel polyposis.
Providing that there was no evidence of small bowel
obstruction, the patient proceeded to CE ("Pillcam
M2A” Capsule, Given Imaging, Yoqneam, Israel), four
weeks later. The technical description is available else-
where [9]. Each patient was required to fast at least 8
hours prior to capsule ingestion, with no additional
bowel preparation given directly prior to their CE and
to remain within the hospital for the 8 hour duration of
the CE transmission period.
An upper gastrointestinal endoscopy using a side-
viewing scope was done one to two weeks after CE,
with the procedure recorded on digital video. Biopsies
w e r et a k e no fp o l y p s> 5m ma sp e rr o u t i n ep r a c t i c ei n
surveillance. Duodenal and small bowel adenomas
d e t e c t e di nt h ec o u r s eo ft h es t u d yw e r em a n a g e do u t -
side the protocol, on clinical merits including with poly-
pectomy or ablative therapy.
Endoscopic examinations were performed by one of
two experienced endoscopists. For all four procedures,
the imaging was read by two investigators with specialty
training and expertise in their procedure (gastroenterol-
ogists for CE and endoscopy, radiologists for SBFT and
MRI). One investigator was blinded to the patient his-
tory and results of all investigations performed on the
patient. The second investigator was not blinded and
read all studies in the series to ensure consistency.
Where there was a discrepancy between findings by the
two investigators, an independent blinded assessor
reviewed the images to decide the findings.
Localisation on CE was determined using known
observable anatomic features of the bowel, including
identification of the major and minor ampullae, pylorus
and ileo-caecal valve. Localization was also judged by
analyzing the time scale between passage through the
pylorus and the ileo-caecal valve, informed by the locali-
zation software provided by Given Imaging.
Pathologic findings were recorded for each imaging
modality. The estimated polyp size and number of
polyps in each segment of the gastrointestinal tract (gas-
tric, duodenum, jejunum, ileum, caecum) was documen-
ted. Numbers of polyps were recorded as 1, 1-4, 5-20
and >20. Size estimation of polyps was recorded as 1-5
mm (small), 6-10 mm (medium) and >10 mm (large)
judged with reference to open biopsies forceps as cali-
bration (standard endoscopy) or with reference to small
bowel morphology. The severity of duodenal polyposis,
classified using a modified version of the Spigelman
classification system was noted, but not used [14].
Student’s t-test/chi square testing were used for a
comparison of polyp numbers and size, and identifica-
tion of abnormal papillae, as estimated by each method.
Analysis of variance was conducted using a General Lin-
ear Model and Two-Way ANOVA. Within the duode-
num sensitivity and specificity of the Capsule was
calculated using the duodenoscopy findings as the “gold
standard”.
Results
A total of 20 patients were investigated in this study.
The average age was 44.7 years (range 19-79) with equal
numbers of males and females.
A square root calculation was performed on the total
polyp numbers to equalize the variance of the
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dataset).(Figure 1) Two-way ANOVA calculation to
compare each modality and region gave p-value < 0.001.
Overall, upper SV endoscopy provided the most find-
ings in the segments of stomach and duodenum, and
CE provided most findings beyond the duodenum. In
the duodenum, upper SV endoscopy identified more
total polyps than the other three procedures for 13
patients and either the same or fewer than CE proce-
dure for 6 patients(p < 0.001). For one patient, no
polyps were detected with either upper GI SV endo-
scopy or CE, whereas SBFT and MRI both identified 5-
20 small polyps for this patient.
When comparing the total number of polyps per size,
upper GISV endoscopy identified more polyps >10 mm
than other modalities, fewer polyps <6 mm than CE and
was similar to CE for polyps 6-10 mm.
Few polyps were diagnosed overall by the barium fol-
low through or MRI, with CE identifying more polyps in
regions other than the duodenum. For all regions the
majority of polyps diagnosed by CE were size <6 mm.
SBFT produced the fewest findings of all investiga-
tions, detecting polyps in 8 of 20 (40%) patients. SBFT
detected stomach polyps in 4 patients, but none greater
than 5 mm were identified. Five patients were diagnosed
with duodenal polyps (2 with polyps <5 mm, 2 with
polyps 6-10 mm and 1 patient with a polyp >10 mm).
Only 1 patient provided findings on SBFT beyond
the duodenum, with 1-4 polyps up to 10 mm in the
jejunum.
MRI studies revealed polyps in 11 of 20 (55%) patients.
These polyps were predominantly localized to the duode-
num, although there was at least one finding for each of
stomach, ileum and caecum. MRI was able to detect a
polyp larger than 10 mm in 5 out of the 11 patients with
polyps of this size; of these, none of the polyps were
located outside the duodenum. In comparison to CE,
MRI detected fewer polyps across all parts of the bowel.
It also detected fewer polyps of all sizes than CE.
Upper GI SV endoscopy was able to identify at least one
finding in 19 of 20 (95%) patients, detecting gastric polyps
in 17 of 20 (85%) and duodenal polyps in 18 of 20 (90%)
of patients. The predominant finding was >20 small (1-5
mm) polyps. No polyps were identified by upper gastroin-
testinal SV endoscopy beyond the duodenum.
The average gastric emptying time measured by the
capsule was 38 minutes (range 3-149 minutes) and the
average small bowel transit time was 4 hours 15 minutes
(range 2.13-7.25 hours). In 3 patients a total small bowel
transit time could not be accurately determined. One of
the capsule studies reported views indicative of the large
bowel, but could not clearly identify the point where the
capsule reached the ileo-caecal valve. In another patient,
the capsule remained in the stomach for the duration of
the study.
CE was the only form of imaging in this study that
identified polyps in all segments of the bowel. It pro-
vided a significantly higher total number of polyp find-
ings in jejunum, ileum and caecum than MRI and SBFT
(Figure 2).
Figure 1 Interval Plot of Score vs Procedure, Sizes, Region.
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endoscopy in stomach and duodenum. This was primar-
ily attributed to CE significantly underestimating num-
ber of polyps in 9 studies. Six of these 9 (66%)
underreported the number of duodenal small (1-5 mm)
polyps, 2 of 9 (22%) underestimated medium polyps (6-
10 mm) and one CE reported a fewer number of >10
mm polyps than for the same patient on upper gastroin-
testinal endoscopy.
Interestingly, CE detected a number of polyps that
were not identified by upper gastrointestinal endoscopy
in some studies. There were 3 findings by CE in the sto-
mach not found on upper gastrointestinal endoscopy
(including 5-20 small polyps and 1 medium polyp). In
the duodenum, CE detected 3 instances of polyps not
found on SV upper gastrointestinal endoscopy (up to 20
small polyps, 1-4 medium and 1-4 large polyps).
In one patient, CE detected a 25 mm bleeding polyp
at the duodeno-jejunal flexure (Figure 3). The polyp was
histologically identified as an advanced adenoma follow-
ing surgical resection. This finding was missed on stan-
dard endoscopy. This case indicates that clinically
significant polyps may be missed with standard SV
endoscopic surveillance and CE may be of benefit as an
adjunctive screening test.
Discussion
Patients with Familial Adenomatous Polyposis have a
greatly increased lifetime risk of developing adenomas
and carcinomas in the colon, stomach and duodenum
[14-16]. These dysplastic lesions may be associated with
significant complications including metastases and
bowel obstruction [17-19]. Treatment of FAP patients
can often be difficult due to the widespread nature of
their polyposis. Total colectomy is recommended for
established large bowel polyposis, but this does not
reduce the risk of adenomatous growths along other
parts of the bowel. Likewise resection of the duodenum
has been found only moderately effective as a treatment
strategy as neoplastic polyps may still develop within
jejunum or ileum after the Whipple’s resection.
The current recommended guideline for treatment
includes regular screening for the detection and moni-
toring of polyps within FAP patients, with colectomy
advised in a timely fashion after establishment of the
diagnosis. SV upper gastrointestinal endoscopy is highly
effective for identifying most polyps within the duode-
num. However the possibility of adenomas developing in
segments of the bowel inaccessible by standard upper GI
endoscopy in a proportion of FAP patients indicates that
additional modes of screening could be considered.
Based on our results. we suggest that both MRI and
SBFT detect significantly fewer gastric and duodenal
polyps compared to upper gastrointestinal SV endoscopy
or CE. Beyond reach of duodenoscopy, however, our
data suggests that MRI and SBFT also detect signifi-
cantly fewer polyps than CE. The low frequency of find-
ings on these two forms of imaging support the
Figure 2 Total number of polyp findings (medium and large).
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unsuitable for primary screening for polyps in FAP
[20-22].
The decreased sensitivity of CE for gastric and med-
ium to large duodenal polyps conforms with previous
experience [23], with a consensus opinion that CE has
limited ability to detect lesions proximal to the ampulla
due to the relatively short transit time by the capsule
through the first part of duodenum. Fast gastric empty-
ing times and the poor ability to localize the capsule
within the stomach could help explain the underestima-
tion of gastric polyps. In light of the high incidence of
polyps around the papilla of Vater, we recommend that
upper gastrointestinal endoscopy should remain the pri-
mary form of screening for duodenal polyps.
Previous research has indicated that CE may have a
significant role in the detection of small bowel pathology
including polyps and cancer [24,25]. Schulmann et al
demonstrated the ability of CE to detect a high fre-
quency of polyps in the distal bowel of FAP patients
[15]. Our data supports these conclusions, with a signifi-
cant range of findings, including medium to large polyps
identified within the jejunum and ileum by CE. However
i nt h i ss t u d yw ew e r eu n a b l et oc o n f i r md i s t a lp o l y p s
with biopsy and it is possible that some abnormalities
identified as polyps may not be adenomatous and could
be other possibilities, for example lymphoid hyperplasia.
CE is also limited by its inability to objectively deter-
mine polyp size due to lack of standard reference. This
may result in the underestimation of polyp size by CE.
There may be a role for the use of ingested standardized
markers [26]. Further investigation of the utility of these
markers in assessing polyp sizes may help establish their
suitability for standard CE protocol.
Published literature has largely ignored the prevalence
of cancer in the jejunum and ileum of FAP patients,
mainly due to the limited accessibility of this region to
upper GI SV endoscopy. One Danish study examining
all causes of death in a FAP population indicated there
may be a small risk of jejunal cancer developing in this
population [6]. Two other studies found a high correla-
tion between the Spigelmen Score and more distal
polyps found on CE [15,27]. Based on these and our
findings we would suggest that CE be considered for
further screening in selected patients with FAP.
Clinically, cancers in the small bowel distal to the
duodenum have not been considered common in FAP.
In so far as adenomas are precursors to cancer, our
findings challenge the usual clinical surveillance strate-
gies of focusing only on the duodenum and colon,
because of the apparent low cancer risk in jejunum and
ileum. Since the formulation of the current standard for
FAP surveillance, there have been multiple develop-
m e n t sw h i c hm a yn e c e s s i t a t eac h a n g ei ns t a n d a r d
practice.
These developments include the increasingly effective
cancer control in the duodenum and colon leading to
increased survival of FAP patients (through polypectomy
or surgery), an uncertain incidence of deaths from disse-
minated adenocarcinoma (?primary in small bowel) and
greater facility to endoscopically remove polyps in the
jejunum and ileum through the advent of double-
balloon enteroscopy. Double-balloon enteroscopy was
not used as an intervention in this study as it was not
available at the time, but it may provide useful informa-
tion to help confirm CE findings in FAP surveillance.
Although double-balloon enteroscopy has the advan-
tages of biopsy and interventional capabilities, CE is a
less invasive procedure and is well tolerated.
Further confirmatory studies might help evaluate the
significance of CE, by assessing the clinical correlation
between distal polyps detected by CE and the
Figure 3 Images taken by CE of a 25 mm bleeding tumour in the jejunum.
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endoscopic techniques, such as double-balloon entero-
scopy with CE might be useful in further defining the
sensitivity and specificity of CE for distal polyps. Our
study has shown CE to be of limited effectiveness for
assessment of gastric and duodenal polyposis, but fre-
quently identifies distal bowel polyps and is likely to be
clinically relevant for a subset of patients at higher risk
of distal small bowel adenomas. These results affirm the
findings of previous studies [21], and suggests that CE
may play an important role within a FAP screening
protocol.
Conclusions
Side-viewing upper GI endoscopy and capsule endo-
scopy were able to detect a significantly higher number
of polyps in the bowel than MRI and small bowel follow
through. Upper GI endoscopy excelled at identifying
polyps in the stomach and duodenum, but a significant
proportion of findings were detected by capsules that
were not seen on standard endoscopy. The low sensitiv-
ity of CE in detecting large duodenal polyps of greatest
clinical relevance indicates that CE would be unsuitable
as a primary screening tool for FAP patients. Capsule
Endoscopy identifies a greater number of bowel polyps
distal to the duodenum in a subset of patients with FAP.
C a p s u l eE n d o s c o p ym a yb eu s e f u la sa na d j u n c ti n
FAP screening and is likely to be clinically relevant for a
subset of patients at higher risk of distal small bowel
adenomas.
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